Navigation Links
Labtec’s Next Generation Pain Patch Successful in Clinical,Studies

LANGENFELD, Germany, April 25, 2007-Labtec GmbH (Langenfeld, Germany), a specialty pharmaceutics company announces positive results from a multiple dose clinical study for their proprietary Sufentanil transdermal patch.

“Today, we are pleased to announce the successful completion of the second clinical trial for our Sufentanil TDS®. Our goal for this program was to complete this study in the first half of 2007,” says Dr. Armin Breitenbach, Labtec's Director of Pharmaceutical Development. “Based on the positive results of the first Phase I trial for our Sufentanil patch that showed good safety, tolerability and extended drug release, we initiated this trial end of last year. The objectives to demonstrate effective plasma levels and safety of repetitive applications of our Sufentanil patch were fully met. We believe that this product, once approved, will provide a significant improvement over currently available pain management therapies on the market today.”

Labtec's transdermal Sufentanil product is intended to provide extended chronic pain relief for several days. The patch is not only very small but at the same time has an unusually low drug content. The proprietary formulation releases the drug with an unparalleled efficiency. Additional patient comfort is achieved by the use of a special non-woven backing. Unlike most backing films used in transdermal systems, this material is non-occlusive, allows the skin to breathe and maintains its integrity throughout the application period.

“After the huge success story of our Fentanyl patch, which is marketed by our licensee ratiopharm and several other leading generic companies in Europe, we are looking forward to see our Sufentanil TDS® move forward. In our opinion this transdermal patch is the logical next generation product for severe chronic pain. Sufentanil is one of the most potent drugs in its class,
'"/>




Page: 1 2

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
4. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
5. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
6. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
10. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
11. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Labtec Next Generation Pain Patch Successful Clinical Studies
(Date:7/23/2008)...CISCO, July 23 /- InCode BioPharmaceu... today announced preclinical test,results demonstr...-1 for,the treatment of the rare chronic blood dis...he complete results will be presented at the XXII,...rland, September 28,2008., The only treatment cu...
(Date:7/22/2008)..., Australia, July 22 /- Fol...rday, the Board of Progen,Pharmaceuticals Limited ...ad discontinued the PI-88 phase 3 study in liver c... develop its existing portfolio of compounds and,t...l compounds and,opportunities through Merger & Acq...
(Date:7/22/2008)...wards under Therapeutics Development Initiative br...to 23; next deadline January 20,2009, NEW YORK, ...mission to,speed delivery of transformative treatm...el J. Fox Foundation for Parkinson,s Research has ...try research teams. The awards,were granted under ...
(Date:7/22/2008)...the-Art PET Study Confirms Tyrima Exhibits Excelle...es - - Results Support Initiation of Phase I..., July 22 /- CeNeRx BioPharma,Inc., ...izing innovative,treatments for diseases of the ce...ance its lead candidate Tyrima(TM) into Phase II t...
Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Quality of Life an Issue in Prostate Cancer Treatment 14764 1Quality of Life an Issue in Prostate Cancer Treatment 14764 2Quality of Life an Issue in Prostate Cancer Treatment 14764 3HHS Secretary Leavitt Praised for Defending Physicians Conscience Rights 14759 1HHS Secretary Leavitt Praised for Defending Physicians Conscience Rights 14759 2Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 1Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 2Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 3Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 4American Idol Spotlights Malaria Crisis During Idol Gives Back April 9 On FOX 14753 1American Idol Spotlights Malaria Crisis During Idol Gives Back April 9 On FOX 14753 2
...-USNewswire/ -- The,following statement may be att...he Advancement of Medical Research (CAMR): , "In t...Bush once,again used the stroke of his veto pen de...d medical research, as well as endanger,the future...,executive order directing NIH to continue pursuin...
...e 2 Diabetes Presented at the,67th Annual Scientif...FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, I...cused on the development,of therapeutics to treat ...on of top line data of its phase 2a study of DIO-9...or for the treatment of,type 2 diabetes. , Results...
Other Medicine Technology:President Bush Ignores America's Plea for Support of Stem Cell,Research 2DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein 2DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein 3
(Date:7/25/2008)...CESS, N.Y., July 25 /PRNewswire-USNewswire/ -- Ant...f Quality Officer and Vice President,of Strategic ...th Fund, a,national foundation committed to improv...ted the foundation,s Program on Health Care Qualit....newscom.com/cgi-bin/prnh/20080725/DC28791LOGO ),...
(Date:7/25/2008)...ON, Calif., July 25 /PRNewswire-FirstCall/ -- Thor...n device-based mechanical,circulatory support ther...,today announced that it will report its operating...hs of fiscal 2008 on Thursday, July 31., The comp...ancial,results and operating activities to all int...
(Date:7/25/2008)...A July 24, 2008 Being overweight or obese is not...ut is also a public health issue that impacts othe...ealth Services Research reveals that the extra Me...ple could place a significant financial burden on ...dollars across the entire current Medicare populat...
(Date:7/25/2008)...July 25 /PRNewswire/ -- BeaconEquity.com announces... news today., Investors can view all of the daily...nEquity.com/m , Today,s Trade Alerts include: DUS...ok Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMed ..., Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis Inc....
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3
...cern over the AIDS crisis ravaging sub-Saharan Afr...'s XIII International AIDS Conference, researchers...many consider to be the next big trouble spot--Ind...ffing, and if there's an enemy of India it's not P...
... high levels of cholesterol but low levels that ar... Low levels of Cholesterol maybe linked to depress...en with relatively low cholesterol levels were up ... severe depression. Edward Suarez, PhD from Duke ...
...uld get a second medical opinion if they are told ...id tumors that could become cancerous.//'It is ver...cerous,' said Dr. Nelson Teng, chief of gynecologi...ool of Medicine.Fibroids are benign growths in the...
... all of you who thought that one only uses cortico...that have come out in the recent years which are d...Using Tacrolimus, the agent which was devised for ...st symptomatic relief of patients. Eczema is a dev...
Other Medicine News:
Every so often a new product comes along that isn't a small step but a giant leap ahead of everything that has preceeded it. Such is the impact of the Fidelity IAB.
...the perfect partner for growing your business prac...e scalable to meet your needs now and in the years...r FD20 system supports mixed-use as well as dedica...ws you to add new applications and techniques such...
...on CFX series represents a breakthrough that makes...ty. Its revolutionary design integrates Quantum 64...ies and advanced software. In fact, Aquilion CFX ... shown a sensitivity of 88% and specificity of 91%...
...2000 represents a new non-invasive approach to the...stem rapidly induces mild hypothermia in those pat...ia or rapidly reduces temperature in febrile patie...aintains core body temperature in a range of 33C (...
Medicine Products: